Questions? 858.450.2800 Schedule a: DEMO
SUDOSCAN® User: LOGIN
Skip to content
  • About SUDOSCAN® USA
    • Device Information
    • In your practice
    • Company
  • Research, News & Events
  • About Us
  • Contact Us
  • SUDOSCAN® Shop
  • Log in
  • Facebook
  • YouTube
  • Twitter
  • LinkedIn
Cart


Subtotal
$0.00
Shipping, taxes, and discount codes calculated at checkout.
Your cart is currently empty.
SUDOSCAN SUDOSCAN SUDOSCAN SUDOSCAN
  • About SUDOSCAN® USA
    • Device Information
    • In your practice
    • Company
  • Research, News & Events
  • About Us
  • Contact Us
  • SUDOSCAN® Shop
Log in Cart

Confirm your age

Are you 18 years old or older?

Come back when you're older

Sorry, the content of this store can't be seen by a younger audience. Come back when you're older.

Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Home / SCIENTIFIC NEWS / The utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy
Diabetes · Scientific publications · Feb 18, 2023

The utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy

The utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy

THE UTILITY OF SUDOSCAN TO DIAGNOSE DIABETIC CARDIOVASCULAR AUTONOMIC NEUROPATHY
AND DIABETIC POLYNEUROPATHY

C. D’amato, C. Greco, G. Lombardo, V. Frattina, M. Campo, C.M.A. Cefalo, V. Izzo, D. Lauro, V. Spallone.

Article title: “The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy”

J Peripher Nerv Syst. 2020 Jan 27.

In a recent study conducted at the university of Rome, Vicenza SPALLONE and her team demonstrated
the utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic neuropathy (CAN) and diabetic polyneuropathy (DPN).

102 diabetic participants were evaluated with the COMPASS 31 questionnaire, a validated questionnaire for autonomic symptoms of CAN, in combination with sudomotor function (sweat gland innervation) testing with SUDOSCAN (results reported as electrochemical skin conductances-ESC). CAN was defined as 2 or more abnormal cardiovascular reflex tests (CARTs); DPN as 2 abnormalities among neuropathic symptoms, signs, vibration perception testing, and thermal thresholds.

In a population with confirmed CAN and DPN, the percentage of abnormal COMPASS 31 + ESC results were 58% and 37%, respectively. These values increase to 100% and 85% when one of the two tests is abnormal (COMPASS 31 and/or ESC), see Figure 1.

The sensitivities and specificities are reported in Table 1. COMPASS 31 and ESC reached a sensitivity of 75% and 83% for confirmed CAN, and a specificity of 65% and 67% for DPN. Both patterns – abnormal COMPASS 31+ESC and abnormal COMPASS 31 and/or ESC – were associated with CAN and DPN (P<0.01). When combining the tests, the sensitivity rose to 100% for CAN and the specificity up to 89% for DPN (reported in Table 2).

These promising results demonstrate the utility of SUDOSCAN combined with a simple questionnaire, COMPASS 31, to identify cardiovascular autonomic neuropathy within a diabetic population and then confirm the diagnosis with specific tools. A normal SUDOSCAN and COMPASS 31 suggest the absence of CAN, while 2 abnormal tests should prompt additional testing with CARTs.


Figure 1

Percentage of pattern COMPASS 31+ESC (abnormality in both measures) and pattern COMPASS 31 and/or ESC (abnormality in at least one measure) in patients with CAN, confirmed CAN and DPN.

Percentage of pattern COMPASS 31+ESC (abnormality in both measures) and pattern COMPASS 31

CAN (≥1 abnormal CART) and confirmed CAN (≥2 abnormal CARTs)


Table 1

Diagnostic characteristics for confirmed CAN and DPN of abnormality in COMPASS 31 or ESC (hands and/or feet): sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictor Value (NPV), Likelihood ratio for positive (LR+) and negative (LR-) results. 95% CI in the brackets.

Diagnostic characteristics for confirmed CAN and DPN of abnormality in COMPASS 31

Table 2

Diagnostic characteristics for confirmed CAN and DPN of pattern COMPASS 31+ESC or Compass 31 and/or ESC: sensitivity, specificity, Positive Predictive Value (PPV), Negative Predictor Value (NPV), Likelihood ratio for positive (LR+) and negative (LR-) results. 95% CI in the brackets.

Diagnostic characteristics for confirmed CAN and DPN of pattern COMPASS 31
Share Share on Facebook Tweet Tweet on Twitter Pin it Pin on Pinterest

Back to SCIENTIFIC NEWS

You may also like View all

Jul 17 2023
Example blog post
Jul 17 2023
Example blog post
Jul 17 2023
Example blog post
Invalid password
Enter
More information about SUDOSCAN®?

Learn why Physicians use SUDOSCAN® during the diagnostic evaluation of Small Fiber and Autonomic Neuropathy for the early detection of potentially treatable diseases. Discover why your patients will appreciate a non-invasive test to monitor their disease and treatment outcome.

Contact Us
Schedule a SUDOSCAN® DEMO

SUDOSCAN® is a patented technology that evaluates sweat gland function, which is controlled by small nerves like some of those involved in pain sensation. Discover how SUDOSCAN® technology is less Invasive and more reliable.

Schedule a DEMO
SUDOSCAN

SUDOSCAN® is a privately-owned French medical device company.

Created in June 2005, its corporate headquarters are located in Paris, France; the company is also present in San Diego, CA, USA and in Beijing, China.

  • Facebook
  • YouTube
  • Twitter
  • LinkedIn

Main menu

  • About SUDOSCAN® USA
  • Research, News & Events
  • About Us
  • Contact Us
  • SUDOSCAN® Shop

Shop SUDOSCAN

  • Sudoscan 3
  • Mobility Kit
  • Benefect Botanical Decon 30
  • Kimtech Science™ Precision Wipes
  • SUDOSCAN® USB Drive

Resources

  • For Physicians
  • For Patients
  • SUDOSCAN® Articles
  • Marketing Material
  • SUDOSCAN® Videos
  • SUDOSCAN® Image Gallery

CONTACT INFO:

OFFICE : SUDOSCAN Inc. 8525 Gibbs Dr. Suite 304 - San Diego, CA 92123

PHONE: +1 858 450 2800

Promotional Communication. The medical devices SUDOSCAN® is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12

Language

  • English
  • Français

Currency

  • Canada (CAD $)
  • United States (USD $)
  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • Shop Pay
  • Visa
© 2023 SUDOSCAN Powered by Shopify
The utility of SUDOSCAN to diagnose diabetic cardiovascular autonomic